Cargando…
Development of an ObLiGaRe Doxycycline Inducible Cas9 system for pre-clinical cancer drug discovery
The CRISPR-Cas9 system has increased the speed and precision of genetic editing in cells and animals. However, model generation for drug development is still expensive and time-consuming, demanding more target flexibility and faster turnaround times with high reproducibility. The generation of a tig...
Autores principales: | Lundin, Anders, Porritt, Michelle J., Jaiswal, Himjyot, Seeliger, Frank, Johansson, Camilla, Bidar, Abdel Wahad, Badertscher, Lukas, Wimberger, Sandra, Davies, Emma J., Hardaker, Elizabeth, Martins, Carla P., James, Emily, Admyre, Therese, Taheri-Ghahfarokhi, Amir, Bradley, Jenna, Schantz, Anna, Alaeimahabadi, Babak, Clausen, Maryam, Xu, Xiufeng, Mayr, Lorenz M., Nitsch, Roberto, Bohlooly-Y, Mohammad, Barry, Simon T., Maresca, Marcello |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7525522/ https://www.ncbi.nlm.nih.gov/pubmed/32994412 http://dx.doi.org/10.1038/s41467-020-18548-9 |
Ejemplares similares
-
Therapeutic Genome Editing With CRISPR/Cas9 in a Humanized Mouse Model Ameliorates α1-antitrypsin Deficiency Phenotype
por: Bjursell, Mikael, et al.
Publicado: (2018) -
Obligate Ligation-Gated Recombination (ObLiGaRe): Custom-designed nuclease-mediated targeted integration through nonhomologous end joining
por: Maresca, Marcello, et al.
Publicado: (2013) -
Whole Organism Genome Editing: Targeted Large DNA Insertion via ObLiGaRe Nonhomologous End-Joining in Vivo Capture
por: Yamamoto, Yutaka, et al.
Publicado: (2015) -
Decoding non-random mutational signatures at Cas9 targeted sites
por: Taheri-Ghahfarokhi, Amir, et al.
Publicado: (2018) -
In vivo genome and base editing of a human PCSK9 knock-in hypercholesterolemic mouse model
por: Carreras, Alba, et al.
Publicado: (2019)